ID
45423
Descrizione
Principal Investigator: Mary V. Relling, PharmD, St. Jude Children Research Hospital, Memphis, TN, USA MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000638 Using risk-directed therapy for childhood acute lymphoblastic leukemia (ALL), outcome has improved dramatically in the last 40 years. However, a substantial portion of patients experience relapse, many of whom have no known risk factors. Taking a genome-wide approach, we sought to evaluate the relationships between germline SNP genotypes and the risk of relapse in 2,535 children with newly diagnosed ALL after adjusting for genetic ancestry and treatment regimen. We examine prognostic value of selected SNPs in the context of known relapse risk factors (molecular subtypes, minimal residual disease, age and leukocyte count at diagnosis). Associations of relapse-related SNPs with pharmacokinetic and pharmacodynamics of antileukemic drugs offer plausible mechanism by which they are linked to treatment outcome. Finally, we aim to identify SNPs that are related to both genetic ancestry and relapse which are likely to contribute to racial disparities in ALL survival.
collegamento
Keywords
versioni (1)
- 25/11/22 25/11/22 - Chiara Middel
Titolare del copyright
Mary V. Relling, PharmD, St. Jude Children Research Hospital, Memphis, TN, USA
Caricato su
25 de noviembre de 2022
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
dbGaP phs000638 Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, and subject source ID of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable obtained from participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Subject ID, clinical protocol, relapse status, gender, and genotype of race of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Sample ID, body site, analyte type, tumor status of sample, and histological type of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, and subject source ID of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable obtained from participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Subject ID, clinical protocol, relapse status, gender, and genotype of race of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
- Sample ID, body site, analyte type, tumor status of sample, and histological type of participants with childhood acute lymphoblastic leukemia and involved in the "Genome-Wide Association Study of Relapse of Childhood Acute Lymphoblastic Leukemia" project.
C0680251 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
C0023449 (UMLS CUI [1,3])
C1519168 (UMLS CUI [1,4])
C1516477 (UMLS CUI [1,5])
C0021430 (UMLS CUI [2,1])
C0162791 (UMLS CUI [2,2])
C0470187 (UMLS CUI [3,1])
C2986526 (UMLS CUI [3,2])
C0242483 (UMLS CUI [4,1])
C1285573 (UMLS CUI [4,2])
C0681814 (UMLS CUI [4,3])